The biggest retatrutide news of the next fortnight isn't a new trial result — it's the moment three press releases finally become a dataset. Eli Lilly has confirmed it will present Phase 3 retatrutide data at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, running 28 September to 2 October 2026, with an EASD-sponsored retatrutide symposium scheduled for Wednesday 30 September, 8:30–9:30am CEST. For anyone following retatrutide news closely, that hour is where the detail behind the headline numbers gets shown to diabetologists rather than to the wire services.

What Is Actually Being Presented in Milan

The retatrutide slot at EASD 2026 covers Phase 3 results for the once-weekly GIP, GLP-1 and glucagon triple receptor agonist — specifically TRIUMPH-2, the trial in adults with obesity or overweight and type 2 diabetes.

TRIUMPH-2's headline is already public. Lilly's 23 July 2026 announcement reported that participants lost up to an average of 22.5 kg (49.6 lb; 20.8% of body weight) and lowered HbA1c by up to an average of 1.6 percentage points at 80 weeks. That was a topline company announcement — a summary of the primary endpoints, not the full analysis.

What a conference symposium typically adds is the material a topline release leaves out: results broken out dose by dose, responder curves, discontinuation and adverse-event tables, how the diabetes cohort's weight loss compares with the non-diabetes cohort, and the efficacy-estimand caveats that decide how the number should be read. It is worth being blunt about the limitation, though: a podium presentation is still not a peer-reviewed publication. Lilly has said detailed TRIUMPH-2 and TRIUMPH-3 results will be presented at medical meetings and published in peer-reviewed journals, and that publication step hasn't happened yet.

Where TRIUMPH-2 Sits in the Programme

TRIUMPH-1, the pivotal obesity trial in people without diabetes, already had its podium moment at the American Diabetes Association Scientific Sessions in June 2026: 2,339 participants, −28.3% average body weight at 12 mg versus −2.2% on placebo at 80 weeks, with 45.3% losing at least 30% of their body weight. Milan makes TRIUMPH-2 the second Phase 3 in the programme to be laid out in full.

That distinction matters because the diabetes number is lower, and consistently so across the GLP-1 class — people with type 2 diabetes lose less weight on incretin therapy than people without it. Seeing the 20.8% figure dissected alongside its glycaemic results is the point of the session. More on the programme structure is in our clinical trials overview.

The Trial That Isn't on the Milan Agenda

TRIUMPH-3, announced on the same July day, tested retatrutide in adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. Weight loss reached up to 22.6% at 80 weeks, alongside reported average reductions of 37.0% in triglycerides, 16.5% in non-HDL cholesterol, 9.3 mmHg in systolic blood pressure and 51.2% in high-sensitivity CRP at the highest dose.

The number that deserves careful reading is the cardiovascular one. Lilly reported 27 MACE-3 events (cardiovascular death, heart attack or stroke) in the retatrutide arms versus 23 on placebo — a hazard ratio of 1.12 with a 95% confidence interval of 0.64 to 1.96. An interval that wide spanning 1.0 means the trial simply wasn't built to answer the cardiovascular outcomes question; it is a safety observation in a trial powered for weight, not a cardiovascular outcomes trial result. It should not be read as evidence of benefit or of harm. We cover how to interpret findings like this on our safety page.

Retatrutide Isn't Lilly's Only Card at EASD 2026

The Milan agenda quietly reframes how retatrutide fits into its own company's pipeline. Alongside the retatrutide symposium, Lilly is presenting:

  • Foundayo (orforglipron) — the daily oral GLP-1 pill, which the FDA approved on 1 April 2026, with a symposium on 1 October covering Phase 3 results from the ACHIEVE type 2 diabetes programme, including ACHIEVE-4 cardiovascular data.
  • eloraTZP — a first look at Phase 2 results for Lilly's combination of eloralintide (a selective amylin receptor agonist) with tirzepatide.

That last one is the interesting company for retatrutide to be keeping. Eloralintide alone produced mean weight reductions of 9.5% to 20.1% versus 0.4% for placebo across arms at 48 weeks in a 263-person Phase 2 trial. Combining it with tirzepatide is a different route to the same destination retatrutide is chasing — three-mechanism weight loss — and it means the triple-agonist idea now has an in-house alternative rather than just external competition. Nothing about eloraTZP's Phase 2 data changes retatrutide's Phase 3 results; it does change the context they'll be read in.

What This Means for Australian Readers

Nothing at EASD alters retatrutide's status here. Retatrutide remains investigational and is not approved by the TGA, and Lilly has indicated regulatory submissions beginning from 2027. Reporting through mid-2026 also points to a planned US filing in the first quarter of 2027, which is the earliest formal step in any jurisdiction.

The practical Australian relevance of Milan is evidentiary rather than regulatory. When retatrutide eventually reaches a TGA dossier, the datasets presented at meetings like EASD — and the peer-reviewed papers that follow them — are the material Australian clinicians, PBAC advisers and prescribers will be arguing over. With roughly 66.8% of Australian adults living with overweight or obesity, the difference between a 20.8% average result in a diabetes population and a 28.3% result without diabetes is exactly the kind of nuance that shapes who a drug is eventually indicated for. Our Australia page tracks the local status as it changes.

New to the compound? Start with what retatrutide is and how a triple agonist differs from semaglutide (Ozempic/Wegovy, one receptor) and tirzepatide (Mounjaro/Zepbound, two).

Want the EASD readout when it lands? Join the free updates list — we send a plain-English summary when new retatrutide data is presented or published.

FAQ

When is retatrutide being presented at EASD 2026?

Lilly has confirmed an EASD-sponsored retatrutide symposium on Wednesday 30 September 2026, from 8:30 to 9:30am CEST, at the 62nd EASD Annual Meeting in Milan (28 September – 2 October). It covers Phase 3 TRIUMPH-2 results.

What did TRIUMPH-2 show?

In adults with obesity or overweight plus type 2 diabetes, Lilly's July 2026 topline announcement reported up to an average 22.5 kg (20.8%) weight loss and up to a 1.6 percentage point reduction in HbA1c at 80 weeks. Full detail is due at EASD; the trial has not yet been published in a peer-reviewed journal.

Has retatrutide been approved anywhere yet?

No. As of September 2026 retatrutide has no marketing authorisation in the United States, European Union, United Kingdom or Australia. It remains an investigational medicine, with Lilly signalling regulatory submissions beginning from 2027.

Is retatrutide better than tirzepatide?

No head-to-head Phase 3 trial of retatrutide against tirzepatide has reported. Comparing across separate trials with different populations and durations is unreliable, so any "better" claim is currently an inference rather than a measured result.

Sources

This article is independent editorial content and is not affiliated with, endorsed by or sponsored by Eli Lilly and Company. Retatrutide is an investigational medicine and is not approved by the TGA or any other regulator. This is general information, not medical advice — talk to a qualified Australian health professional about your own treatment.